Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David C Wheeler

Showing results (371-380 of 455) with videos related to

Pageof 46
Sort By:
European Heart Journal|August 23, 2021
Effects of canagliflozin on serum potassium in people with diabetes and chronic kidney disease: the CREDENCE trialBrendon L Neuen, Megumi Oshima, Vlado Perkovic, et al.
American Heart Journal|December 28, 2020
Effects of canagliflozin on cardiovascular, renal, and safety outcomes in participants with type 2 diabetes and chronic kidney disease according to history of heart failure: Results from the CREDENCE trialAshish Sarraju, JingWei Li, Christopher P Cannon, et al.
Kidney International|December 14, 2020
Insights from CREDENCE trial indicate an acute drop in estimated glomerular filtration rate during treatment with canagliflozin with implications for clinical practiceMegumi Oshima, Meg J Jardine, Rajiv Agarwal, et al.
Kidney International Reports|May 2, 2022
Efficacy and Safety of Dapagliflozin in Patients With CKD Across Major Geographic RegionsPriya Vart, Ricardo Correa-Rotter, Fan Fan Hou, et al.
Kidney360|April 4, 2022
Stroke in Hemodialysis Patients Randomized to Different Intravenous Iron Strategies: A Prespecified Analysis from the PIVOTAL TrialPatrick B Mark, Pardeep S Jhund, Matthew R Walters, et al.
Journal of Diabetes Research|June 9, 2022
Risk Factors for Fracture in Patients with Coexisting Chronic Kidney Disease and Type 2 Diabetes: An Observational Analysis from the CREDENCE TrialTamara K Young, Nigel D Toussaint, Gian Luca Di Tanna, et al.
Diabetes, Obesity & Metabolism|May 10, 2023
The sodium-glucose cotransporter-2 inhibitor canagliflozin does not increase risk of non-genital skin and soft tissue infections in people with type 2 diabetes mellitus: A pooled post hoc analysis from the CANVAS Program and CREDENCE randomized double-blind trialsAmy Kang, Brendan Smyth, Brendon L Neuen, et al.
Kidney International Reports|February 23, 2023
Bone Mineral Density and Vascular Calcification in Children and Young Adults With CKD 4 to 5 or on DialysisAlexander D Lalayiannis, Nicola J Crabtree, Charles J Ferro, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|May 17, 2020
Establishing Core Cardiovascular Outcome Measures for Trials in Hemodialysis: Report of an International Consensus WorkshopEmma O'Lone, Andrea K Viecelli, Jonathan C Craig, et al.
Kidney International Reports|December 19, 2024
Exploring How the Kidney BEAM Physical Activity Digital Health Intervention Improved Mental Health-Related Quality of Life for People Living With Kidney DiseaseEllen M Castle, Roseanne E Billany, Hannah M L Young, et al.
Pageof 46

Showing results (371-380 of 455) with videos related to

Sort By:
Pageof 46
European Heart Journal|August 23, 2021
Effects of canagliflozin on serum potassium in people with diabetes and chronic kidney disease: the CREDENCE trialBrendon L Neuen, Megumi Oshima, Vlado Perkovic, et al.
American Heart Journal|December 28, 2020
Effects of canagliflozin on cardiovascular, renal, and safety outcomes in participants with type 2 diabetes and chronic kidney disease according to history of heart failure: Results from the CREDENCE trialAshish Sarraju, JingWei Li, Christopher P Cannon, et al.
Kidney International|December 14, 2020
Insights from CREDENCE trial indicate an acute drop in estimated glomerular filtration rate during treatment with canagliflozin with implications for clinical practiceMegumi Oshima, Meg J Jardine, Rajiv Agarwal, et al.
Kidney International Reports|May 2, 2022
Efficacy and Safety of Dapagliflozin in Patients With CKD Across Major Geographic RegionsPriya Vart, Ricardo Correa-Rotter, Fan Fan Hou, et al.
Kidney360|April 4, 2022
Stroke in Hemodialysis Patients Randomized to Different Intravenous Iron Strategies: A Prespecified Analysis from the PIVOTAL TrialPatrick B Mark, Pardeep S Jhund, Matthew R Walters, et al.
Journal of Diabetes Research|June 9, 2022
Risk Factors for Fracture in Patients with Coexisting Chronic Kidney Disease and Type 2 Diabetes: An Observational Analysis from the CREDENCE TrialTamara K Young, Nigel D Toussaint, Gian Luca Di Tanna, et al.
Diabetes, Obesity & Metabolism|May 10, 2023
The sodium-glucose cotransporter-2 inhibitor canagliflozin does not increase risk of non-genital skin and soft tissue infections in people with type 2 diabetes mellitus: A pooled post hoc analysis from the CANVAS Program and CREDENCE randomized double-blind trialsAmy Kang, Brendan Smyth, Brendon L Neuen, et al.
Kidney International Reports|February 23, 2023
Bone Mineral Density and Vascular Calcification in Children and Young Adults With CKD 4 to 5 or on DialysisAlexander D Lalayiannis, Nicola J Crabtree, Charles J Ferro, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|May 17, 2020
Establishing Core Cardiovascular Outcome Measures for Trials in Hemodialysis: Report of an International Consensus WorkshopEmma O'Lone, Andrea K Viecelli, Jonathan C Craig, et al.
Kidney International Reports|December 19, 2024
Exploring How the Kidney BEAM Physical Activity Digital Health Intervention Improved Mental Health-Related Quality of Life for People Living With Kidney DiseaseEllen M Castle, Roseanne E Billany, Hannah M L Young, et al.
Pageof 46